BACKGROUND: The role of peroxisome proliferator-activated receptor delta (PPAR δ) in the development and progression of colorectal cancer (CRC) remains controversial. AIMS: We investigated the impact of PPAR δ expression in tissues on liver metastasis of CRC. METHODS: We analyzed samples of primary CRC and matched normal adjacent tissues from 52 patients for the expression of PPAR δ, cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF)-A, and CXC chemokine receptor 4 (CXCR4). Correlations of the molecules expressions with clinical characteristics and prognosis of patients were studied. RESULTS: The number of patients positive for PPAR δ, COX-2, CXCR4, and VEGF-A was 25, 33, 18, and 19, respectively. Among the PPAR δ (+)/COX-2 (+), PPAR δ (-)/COX-2 (+), PPAR δ (+)/COX-2 (-), and PPAR δ (-)/COX-2 (-) patient groups, PPAR δ (+)/COX-2 (+) patients had the highest incidence of liver metastasis (p<0.01). PPAR δ (+)/COX-2 (+) expression was a significant independent prognostic factor (HR=7.108, 95% CI 1.231-41.029, p=0.0283) by Cox proportional analysis. PPAR δ (+)/COX-2 (+) patients had the highest positivity for CXCR4 or VEGF-A in tissues (p<0.01). Among the patients in the CXCR4 (+)/VEGF-A (+), CXCR4 (+)/VEGF-A (-), CXCR4 (-)/VEGF-A (+), and CXCR4 (-)/VEGF-A (-) groups, CXCR4 (+)/VEGF-A (+) patients had the highest incidence of liver metastasis (p<0.01). CONCLUSIONS: The expression of both PPAR δ and COX-2 in tissues may lead to liver metastasis and consequent poor prognosis in CRC patients.
BACKGROUND: The role of peroxisome proliferator-activated receptor delta (PPAR δ) in the development and progression of colorectal cancer (CRC) remains controversial. AIMS: We investigated the impact of PPAR δ expression in tissues on liver metastasis of CRC. METHODS: We analyzed samples of primary CRC and matched normal adjacent tissues from 52 patients for the expression of PPAR δ, cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF)-A, and CXC chemokine receptor 4 (CXCR4). Correlations of the molecules expressions with clinical characteristics and prognosis of patients were studied. RESULTS: The number of patients positive for PPAR δ, COX-2, CXCR4, and VEGF-A was 25, 33, 18, and 19, respectively. Among the PPAR δ (+)/COX-2 (+), PPAR δ (-)/COX-2 (+), PPAR δ (+)/COX-2 (-), and PPAR δ (-)/COX-2 (-) patient groups, PPAR δ (+)/COX-2 (+) patients had the highest incidence of liver metastasis (p<0.01). PPAR δ (+)/COX-2 (+) expression was a significant independent prognostic factor (HR=7.108, 95% CI 1.231-41.029, p=0.0283) by Cox proportional analysis. PPAR δ (+)/COX-2 (+) patients had the highest positivity for CXCR4 or VEGF-A in tissues (p<0.01). Among the patients in the CXCR4 (+)/VEGF-A (+), CXCR4 (+)/VEGF-A (-), CXCR4 (-)/VEGF-A (+), and CXCR4 (-)/VEGF-A (-) groups, CXCR4 (+)/VEGF-A (+) patients had the highest incidence of liver metastasis (p<0.01). CONCLUSIONS: The expression of both PPAR δ and COX-2 in tissues may lead to liver metastasis and consequent poor prognosis in CRC patients.
Authors: X Zuo; Y Wu; J S Morris; J B Stimmel; L M Leesnitzer; S M Fischer; S M Lippman; I Shureiqi Journal: Oncogene Date: 2006-02-23 Impact factor: 9.867
Authors: N Shane Cutler; Ramona Graves-Deal; Bonnie J LaFleur; Zhenqiang Gao; Bruce M Boman; Robert H Whitehead; Erin Terry; Jason D Morrow; Robert J Coffey Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Carl C Schimanski; Stefan Schwald; Nektaria Simiantonaki; Caren Jayasinghe; Ursula Gönner; Vanessa Wilsberg; Theodor Junginger; Martin R Berger; Peter R Galle; Markus Moehler Journal: Clin Cancer Res Date: 2005-03-01 Impact factor: 12.531
Authors: S A Kliewer; B M Forman; B Blumberg; E S Ong; U Borgmeyer; D J Mangelsdorf; K Umesono; R M Evans Journal: Proc Natl Acad Sci U S A Date: 1994-07-19 Impact factor: 11.205
Authors: Amir Abdollahi; Christian Schwager; Jörg Kleeff; Irene Esposito; Sophie Domhan; Peter Peschke; Kai Hauser; Philip Hahnfeldt; Lynn Hlatky; Jürgen Debus; Jeffrey M Peters; Helmut Friess; Judah Folkman; Peter E Huber Journal: Proc Natl Acad Sci U S A Date: 2007-07-24 Impact factor: 11.205
Authors: Xiangsheng Zuo; Zhanglong Peng; Micheline J Moussalli; Jeffrey S Morris; Russell R Broaddus; Susan M Fischer; Imad Shureiqi Journal: J Natl Cancer Inst Date: 2009-05-12 Impact factor: 13.506
Authors: Xiangsheng Zuo; Min Xu; Jiang Yu; Yuanqing Wu; Micheline J Moussalli; Ganiraju C Manyam; Sun Il Lee; Shoudan Liang; Mihai Gagea; Jeffrey S Morris; Russell R Broaddus; Imad Shureiqi Journal: J Natl Cancer Inst Date: 2014-03-28 Impact factor: 13.506
Authors: Dingzhi Wang; Lingchen Fu; Wei Ning; Lixia Guo; Xiaofei Sun; Sudhansu K Dey; Rupesh Chaturvedi; Keith T Wilson; Raymond N DuBois Journal: Proc Natl Acad Sci U S A Date: 2014-04-24 Impact factor: 11.205
Authors: Sun Ah Ham; Taesik Yoo; Jung Seok Hwang; Eun Sil Kang; Won Jin Lee; Kyung Shin Paek; Chankyu Park; Jin-Hoi Kim; Jeong Tae Do; Dae-Seog Lim; Han Geuk Seo Journal: Am J Cancer Res Date: 2014-11-19 Impact factor: 6.166